SUTRO
LIVE

Serial Number

98694731

Owner

Sutro Biopharma, Inc.

Attorney

Karen Won

Filing Date

Aug 12, 2024

Add to watchlist:

No watchlists yet
View on USPTO

SUTRO Trademark

Serial Number: 98694731

SUTRO is a trademark filed by Sutro Biopharma, Inc. on August 12, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Sutro Biopharma, Inc.

111 Oyster Point Blvd.
South San Francisco, CA 94080

Entity Type: 03

Trademark Details

Filing Date

August 12, 2024

Registration Date

Not Registered

Published for Opposition

May 27, 2025

Goods & Services

Pharmaceutical and biological preparations for the immune system targeting immuno-oncology pathways; Pharmaceutical and biological preparations for use in oncology; Pharmaceuticals and biological preparations for prophylactic, diagnostic, and therapeutic use in treating, preventing, and managing cancer; Therapeutic agents for medical use, namely, proteins and derivatives, antibody-drug conjugates, immunostimulatory antibody-drug conjugates, dual conjugates, cytokines, bispecific antibodies, and engineered antibodies for destroying tumor cells and stimulating immune response; Vaccines; Bacterial lysate preparations and bacterial extract preparations, for use in the cell free production of therapeutic proteins and peptides for medical use

Custom manufacturing of pharmaceuticals and therapeutic agents for medical use; Custom manufacturing of bacterial lysate preparations and bacterial extract preparations.

Research and development in the fields of pharmaceuticals, biologics, chemistry, protein engineering, proteins and derivatives, antibody-drug conjugates, immunostimulatory antibody-drug conjugates, dual conjugates, cytokines, bispecific antibodies, engineered antibodies, oncology, and immunology; Providing medical scientific research information in the fields of pharmaceuticals, biologics, chemistry, protein engineering, proteins and derivatives, antibody-drug conjugates, immunostimulatory anti-drug conjugates, cytokines, bispecific antibodies, engineered antibodies, oncology, and immunology; Drug discovery, custom design, and development services featuring therapeutic agents for the treatment and prevention of diseases.

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 25, 2026 EXRA
TEAS STATEMENT OF USE RECEIVED
Feb 24, 2026 EISU
SOU EXTENSION 2 GRANTED
Feb 24, 2026 EX2G
SOU EXTENSION 2 FILED
Feb 24, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 24, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 17, 2026 EXRA
SOU EXTENSION 1 GRANTED
Jan 16, 2026 EX1G
SOU EXTENSION 1 FILED
Jan 16, 2026 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 16, 2026 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 22, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 27, 2025 NPUB
PUBLISHED FOR OPPOSITION
May 27, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 21, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 25, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 22, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 22, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 22, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 20, 2025 GNRN
NON-FINAL ACTION E-MAILED
Feb 20, 2025 GNRT
NON-FINAL ACTION WRITTEN
Feb 20, 2025 CNRT
ASSIGNED TO EXAMINER
Feb 19, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 16, 2025 NWOS
NEW APPLICATION ENTERED
Aug 12, 2024 NWAP